EU Clears Novo’s FREHEMGO for Haemophilia A Prevention
The treatment is approved for adults and children, with monthly, two-weekly or weekly dosing options using a pre-filled pen.
Makkler Newsroom · Nov 14, 03:26 AM · 1 min read
Market closed· · CAD · Data may be delayed
Not enough data
Prices may be delayed and are for informational purposes only - not investment advice.
Profitability and valuation from the filed statements
Answers from price, statements, peer and news data. Not investment advice.
MakklerAI Q&A is open to MakklerPRO members. Upgrade to MakklerPRO